Eur J Cancer. 2023 May 23;188:108-110. doi: 10.1016/j.ejca.2023.04.003. Online ahead of print.
NO ABSTRACT
PMID:37229834 | DOI:10.1016/j.ejca.2023.04.003
Recent Content
- ODAC Decisions Confirm Benefit of Ide-Cel and Cilta-Cel in Earlier Line R/R Myeloma Therapy
- Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in MajesTEC-1
- Real-World Registry on the Pharmacotherapy of Multiple Myeloma and Associated Renal and Pulmonary Impairments in the Greater Gulf Region: Protocol for a Retrospective Real-World Data Study
- Cytomegalovirus Reactivation During Elotuzumab Therapy in Patients with Multiple Myeloma
- Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial
- Unique cutaneous metastasis of multiple myeloma
- Bispecific antibodies for the treatment of relapsed/refractory multiple myeloma: updates and future perspectives
- Clinical Efficacy and Safety of Ixazomib-Containing Regimens in the Treatment of Patients with Multiple Myeloma
- Correlation between CRAB Symptoms and Antioxidant Enzyme Activity in Patients with Multiple Myeloma
- Effects of Different Nutritional Scoring Systems on Prognosis of Elderly Patients with Multiple Myeloma